The drug does not just interact with other diabetes medications
The use of n-3 PUFA is recommended in treatment of hypertriglyceridaemia in patients with very high TG concentration as an adjuvant treatment, and the latest data, especially those concerning highly purified eicosapentaenoic acid (EPA icosapent ethyl), also indicate that this effect, associated with a significant reduction of TG concentration, translates into a significant reduction in cardiovascular events by 25%
Quiero centrarme en un efecto adverso que, sin ser el ms frecuente, se est viendo cada vez ms en las consultas (debido al cada vez ms extenso uso de arGLP-1), sobre todo en pacientes obesos o con sobrepeso (no tanto en diabticos): el estreimiento
It develops when there is excess fat in liver cells due to too much fatty acid uptake in the liver, excess synthesis of fat in the liver, and not enough fat exported out of the liver
It is only for fun because hormone levels cannot confirm gender